Showing 19,681 - 19,700 results of 100,440 for search '(( 5 we decrease ) OR ( 5 ((non decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 2.12s Refine Results
  1. 19681

    Spontaneous apoptosis of neutrophils from patients, asymptomatic carriers and non-carriers. by Robert Blomgran (179794)

    Published 2012
    “…Data are expressed as % FITC-AnnexinV positive cells or as % cells with decreased membrane potential. …”
  2. 19682
  3. 19683

    The expression of Cregs is diminished in the allograft model with the progression of ATCMR. by Kazuaki Yamanaka (2541484)

    Published 2016
    “…Statistical significance was assessed by the t-test and Tukey’s HSD test. (A) qRT-PCR showed significantly diminished expression levels of Crry and CD59 mRNA in the allografts, compared to syngeneic grafts, at day 5 after transplantation. …”
  4. 19684

    Characteristics of cell line models. by Katarzyna Monika Lamperska (4217602)

    Published 2017
    “…The following results were found: A: 8.72; B: 17.44; C22.85; D:37.93, and E:57.89; C) the proliferation ratio generally decreased in the overexpressed let-7d cell line, compared to the controls for the FaDu-GFP line; however, differences between models were not statistically significant, and as such, we did not observe a trend.…”
  5. 19685
  6. 19686

    Experimental Investigation of the Impact of Mixed Wettability on Pore-Scale Fluid Displacement: A Microfluidic Study by Abdullah AlOmier (20402765)

    Published 2024
    “…By systematically varying the ratio of hydrophilic to hydrophobic areas, we covered a range from fully hydrophilic to fully hydrophobic and intermediate mixed wettability configurations. …”
  7. 19687

    Experimental Investigation of the Impact of Mixed Wettability on Pore-Scale Fluid Displacement: A Microfluidic Study by Abdullah AlOmier (20402765)

    Published 2024
    “…By systematically varying the ratio of hydrophilic to hydrophobic areas, we covered a range from fully hydrophilic to fully hydrophobic and intermediate mixed wettability configurations. …”
  8. 19688
  9. 19689

    Image_10_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.t... by Tabassom Mohajershojai (9441050)

    Published 2022
    “…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a <sup>177</sup>Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of <sup>177</sup>Lu-DOTA-M5A and/or onalespib were investigated. …”
  10. 19690

    Image_1_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

    Published 2022
    “…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a <sup>177</sup>Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of <sup>177</sup>Lu-DOTA-M5A and/or onalespib were investigated. …”
  11. 19691

    Image_4_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

    Published 2022
    “…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a <sup>177</sup>Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of <sup>177</sup>Lu-DOTA-M5A and/or onalespib were investigated. …”
  12. 19692

    Image_3_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

    Published 2022
    “…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a <sup>177</sup>Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of <sup>177</sup>Lu-DOTA-M5A and/or onalespib were investigated. …”
  13. 19693

    Image_8_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

    Published 2022
    “…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a <sup>177</sup>Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of <sup>177</sup>Lu-DOTA-M5A and/or onalespib were investigated. …”
  14. 19694

    Image_6_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

    Published 2022
    “…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a <sup>177</sup>Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of <sup>177</sup>Lu-DOTA-M5A and/or onalespib were investigated. …”
  15. 19695

    Image_9_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

    Published 2022
    “…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a <sup>177</sup>Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of <sup>177</sup>Lu-DOTA-M5A and/or onalespib were investigated. …”
  16. 19696

    Image_7_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

    Published 2022
    “…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a <sup>177</sup>Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of <sup>177</sup>Lu-DOTA-M5A and/or onalespib were investigated. …”
  17. 19697

    Image_2_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

    Published 2022
    “…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a <sup>177</sup>Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of <sup>177</sup>Lu-DOTA-M5A and/or onalespib were investigated. …”
  18. 19698

    Table_1_Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.docx by Ron Milo (22493)

    Published 2022
    “…</p>Methods<p>522 PwMS and 68 healthy controls vaccinated with BNT162b2-Pfizer mRNA vaccine against SARS-CoV-2, or recovering from COVID-19, were recruited in a nation-wide multi-center study. …”
  19. 19699

    Table_2_Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.docx by Ron Milo (22493)

    Published 2022
    “…</p>Methods<p>522 PwMS and 68 healthy controls vaccinated with BNT162b2-Pfizer mRNA vaccine against SARS-CoV-2, or recovering from COVID-19, were recruited in a nation-wide multi-center study. …”
  20. 19700

    Table_3_Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.docx by Ron Milo (22493)

    Published 2022
    “…</p>Methods<p>522 PwMS and 68 healthy controls vaccinated with BNT162b2-Pfizer mRNA vaccine against SARS-CoV-2, or recovering from COVID-19, were recruited in a nation-wide multi-center study. …”